ESMO Media Releases
TAT 2020 Honorary Award: a Recognition in Cancer Drug Development to Lillian Siu
ESMO is pleased to announce that Lillian L. Siu will receive the TAT 2020 Honorary Award for her contributions in the development of new anticancer drugs.
From the Basics of Immunotherapies to the Latest Research Results
The platform in Europe devoted entirely to the development and use of the immunotherapies against cancer, will take place from 11-14 December in Geneva, Switzerland with thousand participants from all over the world.
First China-manufactured Trastuzumab Biosimilar HLX02 Global Phase III Trial Met Primary Endpoint in Breast Cancer
SINGAPORE- The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study to be reported at the ESMO Asia Congress 2019.
Combination of Immunotherapy and VEGF Inhibitor Improves Survival in Hepatocellular Carcinoma
SINGAPORE – Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress.
Advances in Cancer Prevention, Treatment and Care Get Prime Time at the ESMO Asia Congress 2019
Over 3,500 medical professionals are convening for the three-day scientific and educational congress to drive progress and contribute to shaping the oncology roadmap in the Asia-Pacific region
2019 ESMO Award for Immuno-Oncology goes to Thomas Gajewski
The European Society for Medical Oncology has selected Prof. Thomas Gajewski to receive the 2019 ESMO Award for Immuno-Oncology.
First Targeted Therapy for Cholangiocarcinoma Shows Clinical Benefit in Phase III Trial
New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma.
Targeted Therapy Slows Progression of Advanced Prostate Cancer
Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer in men.
Adding Immunotherapy to Chemotherapy Prolongs Progression Free Survival in Bladder Cancer
Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy and chemotherapy instead of chemotherapy alone, according to late breaking results of the IMvigor130 trial presented at the ESMO Congress 2019 in Barcelona, Spain.
Mesothelioma Trial Suggests Immunotherapy as an Alternative to Chemotherapy
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year.